A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Latest Information Update: 04 Jul 2024
At a glance
- Drugs Atezolizumab (Primary) ; Zanzalintinib (Primary) ; Regorafenib
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms STELLAR-303
- Sponsors Exelixis
- 04 Jun 2024 Results assessing efficacy and safety of zanzalintinib + atezolizumab in patients with non-MSI-H mCRC, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 18 Jan 2024 Planned number of patients changed from 600 to 874.
- 01 Jul 2023 Trial design presented at the 25th World Congress on Gastrointestinal Cancer